VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions

PURPOSE: The aim of this retrospective study is to evaluate patient profile, feasibility, and acute toxicity of RadioTherapy (RT) delivered by VERO® in the first 20 months of clinical activity. METHODS: Inclusion criteria: 1) adult patients; 2) limited volume cancer (M0 or oligometastatic); 3) small...

Descripción completa

Detalles Bibliográficos
Autores principales: Orecchia, R, Surgo, A, Muto, M, Ferrari, A, Piperno, G, Gerardi, MA, Comi, S, Garibaldi, C, Ciardo, D, Bazani, A, Golino, F, Pansini, F, Fodor, C, Romanelli, P, Maestri, D, Scroffi, V, Mazza, S, Jereczek-Fossa, BA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045299/
https://www.ncbi.nlm.nih.gov/pubmed/27729942
http://dx.doi.org/10.3332/ecancer.2016.677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045299/
https://www.ncbi.nlm.nih.gov/pubmed/27729942
http://dx.doi.org/10.3332/ecancer.2016.677

Ejemplares similares